The Protective Effect of Bajijiasu on the Treatment of Hypertensive Nephropathy in Rats.

IF 2.4 4区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current molecular pharmacology Pub Date : 2023-01-01 DOI:10.2174/1874467215666221005141210

Minyi Li, Beifeng Lie, Tingting Duan, Deqi Chen, Tao Xia, Heng Xie, Guixuan Lin, Junzheng Yang, Zhenghai Li

{"title":"The Protective Effect of Bajijiasu on the Treatment of Hypertensive Nephropathy in Rats.","authors":"Minyi Li, Beifeng Lie, Tingting Duan, Deqi Chen, Tao Xia, Heng Xie, Guixuan Lin, Junzheng Yang, Zhenghai Li","doi":"10.2174/1874467215666221005141210","DOIUrl":null,"url":null,"abstract":"Backgrounds: Hypertensive nephropathy (HN) is a kind of renal disease caused by essential hypertension that eventually worsens into end-stage renal disease (ESRD). HN could damage the renal tubules, induce kidney damage and renal failure, and increase the risk of stroke, heart disease or death, but there are few ideal drugs for HN treatment.Methods: In this study, we explored the therapeutic effect of bajijiasu (a compound from Morinda officinalis how and a common traditional Chinese medicine for tonifying the kidney) on the HN rat model. Biochemical analysis, HE staining, and PAS staining were used to assess the effects of bajijiasu on HN rat model. Western blotting was used to analyze the potential mechanisms.Results: The results of HE staining and PAS staining showed that bajijiasu could alleviate the pathological changes in HN rat models; biochemical analysis found that the concentration of Malondialdehyde (MDA), total protein (TP), albumin (ALB), microalbuminuria (MALB), blood urea nitrogen (BUN), creatinine (Cr), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) were significantly decreased compared with the model group after bajijiasu treatment; and bajijiasu could regulate the expression of TNF-α, IL-6, MDA, SOD1 and AGEs in HN rats; the result of western blotting demonstrated that bajijiasu could down-regulate the expression of TGFβ1, NOX4, JNK, p- JNK and up-regulate the expression PPARγ and SOD 1 in HN rats.Conclusion: Those results demonstrated that bajijiasu could alleviate the pathological changes and physiological and biochemical symptoms of HN rat models by regulating the expression of TGFβ1, PPARγ, JNK, p-JNK, NOX4 and SOD1 but could not lower the blood pressure of HN rats. Those pieces of evidence may provide a new therapeutic method for HN treatment.","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current molecular pharmacology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.2174/1874467215666221005141210","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Backgrounds: Hypertensive nephropathy (HN) is a kind of renal disease caused by essential hypertension that eventually worsens into end-stage renal disease (ESRD). HN could damage the renal tubules, induce kidney damage and renal failure, and increase the risk of stroke, heart disease or death, but there are few ideal drugs for HN treatment.

Methods: In this study, we explored the therapeutic effect of bajijiasu (a compound from Morinda officinalis how and a common traditional Chinese medicine for tonifying the kidney) on the HN rat model. Biochemical analysis, HE staining, and PAS staining were used to assess the effects of bajijiasu on HN rat model. Western blotting was used to analyze the potential mechanisms.

Results: The results of HE staining and PAS staining showed that bajijiasu could alleviate the pathological changes in HN rat models; biochemical analysis found that the concentration of Malondialdehyde (MDA), total protein (TP), albumin (ALB), microalbuminuria (MALB), blood urea nitrogen (BUN), creatinine (Cr), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) were significantly decreased compared with the model group after bajijiasu treatment; and bajijiasu could regulate the expression of TNF-α, IL-6, MDA, SOD1 and AGEs in HN rats; the result of western blotting demonstrated that bajijiasu could down-regulate the expression of TGFβ1, NOX4, JNK, p- JNK and up-regulate the expression PPARγ and SOD 1 in HN rats.

Conclusion: Those results demonstrated that bajijiasu could alleviate the pathological changes and physiological and biochemical symptoms of HN rat models by regulating the expression of TGFβ1, PPARγ, JNK, p-JNK, NOX4 and SOD1 but could not lower the blood pressure of HN rats. Those pieces of evidence may provide a new therapeutic method for HN treatment.

查看原文本刊更多论文

八极加素对大鼠高血压肾病的保护作用。

背景:高血压肾病(hypertension nephropathy, HN)是一种由原发性高血压引起并最终恶化为终末期肾病(end-stage renal disease, ESRD)的肾脏疾病。HN可损害肾小管，引起肾损害和肾功能衰竭，增加中风、心脏病或死亡的风险，但目前治疗HN的理想药物很少。方法:本研究探讨巴吉加苏(巴戟天化合物，补肾中药)对HN大鼠模型的治疗作用。采用生化分析、HE染色、PAS染色评价八鸡甲素对HN大鼠模型的影响。采用免疫印迹法分析其潜在机制。结果:HE染色和PAS染色结果显示，八鸡甲素能减轻HN大鼠模型的病理改变;生化分析发现，与模型组比较，八甲加素治疗后大鼠血清丙二醛(MDA)、总蛋白(TP)、白蛋白(ALB)、微量尿白蛋白(MALB)、血尿素氮(BUN)、肌酐(Cr)、甘油三酯(TG)、低密度脂蛋白-胆固醇(LDL-C)浓度显著降低;八极加素可调节HN大鼠TNF-α、IL-6、MDA、SOD1、AGEs的表达;western blotting结果显示，八鸡甲素可下调HN大鼠tgf - β1、NOX4、JNK、p- JNK的表达，上调PPARγ和SOD 1的表达。结论:八甲加素可通过调节tgf - β1、PPARγ、JNK、p-JNK、NOX4、SOD1的表达，减轻HN大鼠模型的病理变化和生理生化症状，但不能降低HN大鼠的血压。这些证据可能为HN治疗提供一种新的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current molecular pharmacology Pharmacology, Toxicology and Pharmaceutics-Drug Discovery

CiteScore

4.90

自引率

3.70%

发文量

112

期刊介绍： Current Molecular Pharmacology aims to publish the latest developments in cellular and molecular pharmacology with a major emphasis on the mechanism of action of novel drugs under development, innovative pharmacological technologies, cell signaling, transduction pathway analysis, genomics, proteomics, and metabonomics applications to drug action. An additional focus will be the way in which normal biological function is illuminated by knowledge of the action of drugs at the cellular and molecular level. The journal publishes full-length/mini reviews, original research articles and thematic issues on molecular pharmacology. Current Molecular Pharmacology is an essential journal for every scientist who is involved in drug design and discovery, target identification, target validation, preclinical and clinical development of drugs therapeutically useful in human disease.